IGM Biosciences, Inc. is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. The company's proprietary IgM platform technology allows for the development of IgM antibodies that are designed to improve upon the efficacy and safety of traditional IgG antibodies. IGM Biosciences is headquartered in Menlo Park, California and was founded in 2010.